Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

21 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-07-23

Study Completion Date

2020-01-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an open-label, multicenter study to evaluate the systemic exposure and safety of topical tapinarof cream, 1% under conditions of maximal use in adults with plaque psoriasis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003)

NCT04053387

Plaque Psoriasis

COMPLETED PHASE3

Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001)

NCT03956355

Plaque Psoriasis

COMPLETED PHASE3

Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002)

NCT03983980

Plaque Psoriasis

COMPLETED PHASE3

Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects

NCT05172726

Plaque Psoriasis

ACTIVE_NOT_RECRUITING PHASE3

A Study to Investigate Efficacy and Safety of VTAMA (Tapinarof) Cream, 1% in Intertriginous Plaque Psoriasis

NCT05680740

Psoriasis

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Plaque Psoriasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Open-label, single arm study

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Tapinarof (DMVT-505) cream, 1%

Tapinarof (DMVT-505) cream, 1% applied topically once daily

Group Type EXPERIMENTAL

Tapinarof cream, 1%

Intervention Type DRUG

Tapinarof cream, 1% applied topically once daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tapinarof cream, 1%

Tapinarof cream, 1% applied topically once daily

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

DMVT-505

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female subjects age 18 to 75 with a confirmed clinical diagnosis of plaque psoriasis and stable disease for at least 6 months prior to the study
* BSA involvement ≥ 20%
* PGA score of ≥ 3 at screening
* Females of child bearing potential and male subjects who are engaging in sexual activity that could lead to pregnancy agree to follow the specified contraceptive guidance throughout the study
* Capable of giving written informed consent

Exclusion Criteria

* Psoriasis other than plaque variant
* Any sign of infection of any of the psoriatic lesions
* Evidence of significant hepatic, renal, respiratory, endocrine, hematologic, neurologic, psychiatric, or cardiovascular (CV) system abnormalities or laboratory abnormality that will affect the health of the subject or interfere with the interpretation of the results
* Ultraviolet (UV) light therapy or prolonged exposure to natural or artificial sources of UV radiation within 4 weeks prior to the Baseline visit and/or plans to have such exposures during the study which could potentially impact the subject's psoriasis
* Use of any prohibited medication within the indicated period before the first dose of study drug
* Pregnant females or lactating females
* The subject has received an investigational product within 30 days, 5 half-lives, or twice the duration of the biological effect of the study drug (whichever is longer) prior to first dose of study drug
* Current or a history of cancer within 5 years except for fully excised skin basal cell carcinoma, squamous cell carcinoma or carcinoma in situ of the cervix
* Previous known participation in a clinical study with tapinarof

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No